(SYRE) Spyre Therapeutics - Overview
Stock: Antibody, Integrin, TL1A, IL-23, Combination
| Risk 5d forecast | |
|---|---|
| Volatility | 73.9% |
| Relative Tail Risk | 0.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.84 |
| Alpha | 26.83 |
| Character TTM | |
|---|---|
| Beta | 1.571 |
| Beta Downside | 1.766 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.22% |
| CAGR/Max DD | 0.48 |
Description: SYRE Spyre Therapeutics January 19, 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotech focused on inflammatory bowel disease (IBD). Its lead candidate, SPY001, is a human IgG1 monoclonal antibody that selectively blocks the α4β7 integrin, a proven target in ulcerative colitis and Crohn’s disease. The pipeline also includes SPY002 (anti-TL1A), SPY120 (a SPY001 + SPY002 combo), and early-stage programs targeting IL-23 (SPY003) and various antibody combinations (SPY004, SPY130, SPY230). The company, formerly Aeglea BioTherapeutics, rebranded in November 2023 and is headquartered in Waltham, Massachusetts.
Key sector context: the global IBD therapeutics market is projected to exceed $15 billion by 2028, driven by rising prevalence and a shift toward biologics with differentiated mechanisms. Spyre’s cash runway, disclosed in its latest 10-Q, is approximately $45 million, sufficient to fund preclinical work and a Phase 1/2 read-out for SPY001 through mid-2025. Recent industry data show that anti-α4β7 agents (e.g., vedolizumab) command premium pricing (~$40,000 / patient / year), suggesting comparable revenue potential if Spyre can demonstrate differentiated efficacy or safety.
For a deeper dive into Spyre’s valuation metrics, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -149.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 3.84 > 1.0 |
| NWC/Revenue: 51.7k% < 20% (prev 34.9k%; Δ 16.8k% < -1%) |
| CFO/TA -0.32 > 3% & CFO -161.9m > Net Income -149.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.4m) vs 12m ago 18.72% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.19% > 50% (prev 0.25%; Δ -0.06% > 0%) |
| Interest Coverage Ratio: -2.64 > 6 (EBITDA TTM -177.9m / Interest Expense TTM 21.3m) |
Altman Z'' -15.00
| A: 0.91 (Total Current Assets 504.6m - Total Current Liabilities 46.3m) / Total Assets 504.6m |
| B: -2.11 (Retained Earnings -1.07b / Total Assets 504.6m) |
| C: -0.12 (EBIT TTM -56.3m / Avg Total Assets 462.8m) |
| D: -21.50 (Book Value of Equity -1.06b / Total Liabilities 49.5m) |
| Altman-Z'' Score: -24.31 = D |
What is the price of SYRE shares?
Over the past week, the price has changed by +9.82%, over one month by +15.79%, over three months by +56.86% and over the past year by +47.19%.
Is SYRE a buy, sell or hold?
- StrongBuy: 10
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SYRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56.4 | 60.7% |
| Analysts Target Price | 56.4 | 60.7% |
| ValueRay Target Price | 34.5 | -1.7% |
SYRE Fundamental Data Overview February 03, 2026
P/B = 8.2886
Revenue TTM = 886.0k USD
EBIT TTM = -56.3m USD
EBITDA TTM = -177.9m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 84.6m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -64.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.08b USD (2.48b + Debt 84.6m - CCE 486.2m)
Interest Coverage Ratio = -2.64 (Ebit TTM -56.3m / Interest Expense TTM 21.3m)
EV/FCF = -12.85x (Enterprise Value 2.08b / FCF TTM -161.9m)
FCF Yield = -7.78% (FCF TTM -161.9m / Enterprise Value 2.08b)
FCF Margin = -18.3k% (FCF TTM -161.9m / Revenue TTM 886.0k)
Net Margin = -16.8k% (Net Income TTM -149.0m / Revenue TTM 886.0k)
Gross Margin = -5007 % ((Revenue TTM 886.0k - Cost of Revenue TTM 45.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.12 (Enterprise Value 2.08b / Total Assets 504.6m)
Interest Expense / Debt = 25.20% (Interest Expense 21.3m / Debt 84.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -44.5m (EBIT -56.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.90 (Total Current Assets 504.6m / Total Current Liabilities 46.3m)
Debt / Equity = 0.19 (Debt 84.6m / totalStockholderEquity, last quarter 455.1m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -64.9m / EBITDA -177.9m)
Debt / FCF = 0.40 (negative FCF - burning cash) (Net Debt -64.9m / FCF TTM -161.9m)
Total Stockholder Equity = 477.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.19% (Net Income -149.0m / Total Assets 504.6m)
RoE = -31.18% (Net Income TTM -149.0m / Total Stockholder Equity 477.8m)
RoCE = -12.28% (EBIT -56.3m / Capital Employed (Total Assets 504.6m - Current Liab 46.3m))
RoIC = -13.81% (negative operating profit) (NOPAT -44.5m / Invested Capital 322.0m)
WACC = 11.97% (E(2.48b)/V(2.57b) * Re(11.70%) + D(84.6m)/V(2.57b) * Rd(25.20%) * (1-Tc(0.21)))
Discount Rate = 11.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 66.84%
Fair Price DCF = unknown (Cash Flow -161.9m)
EPS Correlation: 79.73 | EPS CAGR: 4.83% | SUE: 0.56 | # QB: 0
Revenue Correlation: -68.72 | Revenue CAGR: -80.21% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.68 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=-2.80 | Chg30d=-0.021 | Revisions Net=+4 | Growth EPS=-32.3% | Growth Revenue=+0.0%